Beside the potential as therapeutic target, PRDM16 expression might be a more refined prognostic tool in NPM1-mutated AML, complementing existing risk stratification systems that rely on genetic abnormalities such as FLT3-ITD. The gene discussed is FLT3; the disease is acute myeloid leukemia.